How long does Wegovy take to work?
- A week-by-week and month-by-month timeline of what to expect
- How quickly Wegovy suppresses appetite
- When weight loss typically starts
- How long you are likely to take Wegovy for
- What affects how quickly it works
- What to do if results are slower than expected
- How long does it take for Wegovy to suppress appetite?
- When does weight loss start on Wegovy?
- How long should you stay on Wegovy for weight loss?
- How long does it take for Wegovy to work at each dose stage?
- What factors affect how quickly Wegovy works?
- What to do if Wegovy is not working as expected
- Final thoughts
Timeline overview: What to expect and when
The table below draws on STEP 1 trial data (New England Journal of Medicine, 2021) and clinical experience from regulated UK weight management services. It represents average expectations, not guarantees. Individual results vary.
| Timeframe | What typically happens |
|---|---|
| Within 24–48 hours | Subtle appetite changes; earlier fullness during meals |
| Week 1–2 | More consistent appetite suppression; food feels less urgent |
| Week 4 | Steady-state blood levels reached; early weight loss beginning |
| Month 1 (0.25–0.5 mg) | Average 2–4% body weight loss in trials; clothes may feel looser |
| Month 2 (0.5–1 mg) | Appetite suppression strengthens; average 4–6% body weight loss |
| Month 3 (1–1.7 mg) | Changes become visible to others; average around 9% body weight loss |
| Month 6 (2.4 mg) | Most significant phase of weight loss; average 12–15% body weight loss |
| Month 12 onwards | Continued loss at slower rate; results plateau as body adapts |
| 68–72 weeks | Average total weight loss of 14.9% at 2.4 mg (STEP 1); 20.7% at 7.2 mg (STEP UP) |
All figures are trial averages. Real-world outcomes are meaningful but typically slightly lower, reflecting variation in dietary adherence, activity levels, and dose reached.
How long does it take for Wegovy to suppress appetite?
Most people notice some reduction in appetite within the first 24 to 48 hours of their first injection. This reflects early GLP-1 receptor activation in the hypothalamus, the region of the brain responsible for regulating hunger and satiety.
In the first week, appetite changes are often subtle. Meals may feel slightly easier to stop, cravings may feel less insistent, or the habitual urge to snack between meals may quietly reduce. These early signals are real, even if they do not feel dramatic.
By weeks two to four, appetite suppression typically becomes more consistent across the week, though some people notice it fades slightly four to five days after the injection before picking up again as the next dose approaches. This pattern often stabilises as blood levels of semaglutide reach a steady state (a stable concentration maintained in the bloodstream from week to week) after approximately four weeks.
Good to know
The reduction in what many patients describe as "food noise" (the constant background preoccupation with food, hunger, and cravings) is often the first change people notice, and for many it is the most significant. The scales may not have moved yet, but the relationship with food has already begun to change.
When does weight loss start on Wegovy?
For most people, measurable weight loss begins between weeks two and four, though the first changes are often modest and may partly reflect water loss rather than fat.
The 0.25 mg starting dose is sub-therapeutic, meaning it is not expected to produce significant weight loss on its own. Its purpose is to allow the body to adjust to semaglutide and minimise gastrointestinal side effects. Meaningful fat loss typically begins as the dose increases and appetite suppression strengthens.
What the clinical evidence shows
In the STEP 1 trial, average weight loss at each stage was as follows:
- Month 1: Approximately 2–4% of starting body weight
- Month 2: Approximately 4–6%
- Month 3: Approximately 9%
- Month 6: Approximately 12–15%
- 68 weeks: 14.9% at the 2.4 mg maintenance dose
To put this in practical terms: a person starting at 100 kg would expect to lose approximately 9 kg by month three and approximately 15 kg by 68 weeks at the standard maintenance dose, based on trial averages.
Good to know
If the scales have not moved in the first two weeks, this is entirely normal and should not cause alarm. The physiological changes are underway before they become visible on the scales.
How long should you stay on Wegovy for weight loss?
Wegovy is designed as a long-term treatment, not a short course. The STEP clinical trial programme measured outcomes at 68 to 72 weeks, and real-world evidence supports continued benefits with sustained use.
There are two important reasons for this.
Weight loss continues over time
The largest changes in body weight are typically seen between months three and twelve. Stopping treatment early, before reaching the maintenance dose or before results have fully accumulated, significantly limits outcomes.
Weight regain after stopping
The STEP 1 extension trial found that participants who discontinued semaglutide after successful weight loss regained approximately two-thirds of their lost weight within 52 weeks. This reflects the chronic nature of obesity as a condition, rather than a personal failure. The underlying biological drivers of excess weight do not resolve with a short course of medication.
NICE guidance recommends a formal clinical review at six months to assess whether treatment is producing sufficient benefit (at least 5% of starting body weight lost), and a further review at 12 months to consider whether ongoing treatment is appropriate. Most patients who are responding well continue beyond 12 months.
For private patients, long-term treatment represents a significant financial commitment. This is worth discussing with your prescriber early, alongside NHS eligibility and whether transitioning to a specialist service may be possible.
How long does it take for Wegovy to work at each dose stage?
Each time the dose is increased, the body goes through a brief adjustment period before the full appetite-suppressing effect of the new dose is felt. Understanding this pattern prevents unnecessary discouragement in the days following a dose increase.
0.25 mg (weeks 1–4)
The starting dose produces mild appetite changes for most people but is not designed to produce significant weight loss. This phase is about tolerability, not results.
0.5 mg (weeks 5–8)
The first genuinely therapeutic dose for many patients. Appetite suppression typically strengthens noticeably at this stage. Some people experience a brief return of side effects such as nausea in the first two to three days after increasing, which usually settles within a week.
1 mg (weeks 9–12)
Most people experience consistent and meaningful appetite reduction at 1 mg. Energy levels often begin to improve as weight starts to come down. Early visible changes in the face and waist become apparent for some patients.
1.7 mg (weeks 13–16)
Appetite suppression typically reaches a level where portion sizes have reduced naturally and snacking has largely stopped. Weight loss is usually well established at this stage.
2.4 mg (week 17 onwards)
The standard maintenance dose. This is where the most sustained weight loss occurs. The body has now adjusted to semaglutide, and the full therapeutic effect is consistently active throughout the week. Results continue to build over months on this dose.
7.2 mg (for eligible patients, from January 2026)
The higher maintenance dose, approved by the MHRA on 6 January 2026, produces average weight loss of 20.7% over 72 weeks in the STEP UP trial. It is indicated for patients who have reached and tolerated the 2.4 mg dose and require additional support to continue progressing.
What factors affect how quickly Wegovy works?
Results vary between individuals. The following are the most clinically significant factors.
Starting dose and titration pace
The 0.25 mg starter dose has a modest effect on appetite and minimal effect on weight. Results accelerate meaningfully as the dose increases. Patients who titrate to higher doses consistently achieve better outcomes.
Diet and lifestyle
Wegovy changes the biology of appetite; it does not replace the habits. People who reduce portion sizes, limit ultra-processed foods, and increase physical activity alongside treatment consistently achieve better and faster outcomes than those who rely on medication alone. This is consistently the most powerful modifying factor in real-world data.
Starting weight and metabolic health
People with higher starting weights tend to see larger absolute losses in kilograms, while percentage loss is broadly comparable across body sizes. Those with underlying insulin resistance or type 2 diabetes may respond slightly differently, though Wegovy is effective in both groups.
Consistency of dosing
Missing doses disrupts the stable blood levels of semaglutide that drive consistent appetite suppression. Injecting on the same day each week, at a consistent time, produces the most stable and predictable results.
Individual metabolism
Factors including thyroid function, gut microbiome, insulin sensitivity, and genetics all play a role in how quickly the body responds. These are not fully predictable or modifiable, but they do mean that some people respond more rapidly than others even at the same dose.
What to do if Wegovy is not working as expected
If you are not seeing the results you expected, the following steps are worth working through before concluding that the treatment is not effective for you.
Check where you are in the titration schedule
If you are still on the starter or early titration doses (0.25–0.5 mg), it is too early to judge effectiveness. Give treatment at least two to three months at a therapeutic dose (1 mg and above) before drawing conclusions.
Review your diet honestly
The most common reason for slower-than-expected progress is insufficient change in dietary habits. Wegovy makes it easier to eat less; it does not automatically produce a calorie deficit. A review of portion sizes, food choices, and eating patterns is often the most productive first step.
Check your dosing consistency
Review whether you have missed any doses or varied your injection day significantly. Even one or two missed doses can noticeably affect appetite suppression in the days that follow.
Speak to your prescriber about escalating
If you have been on a dose for more than eight weeks without progress and are tolerating it well, a dose increase may be appropriate. Do not increase your dose without prescriber guidance.
Recognise a normal plateau
Weight loss plateaus, particularly around months five to eight, are physiologically expected. The body adapts to a lower calorie intake and lower weight. A plateau does not mean Wegovy has stopped working. Revisiting dietary habits and increasing activity are the most evidence-based responses.
Request a clinical review
NICE guidance recommends a review at six months. If you have not lost at least 5% of your starting body weight by this point, your prescriber will discuss whether continuing treatment is appropriate, or whether a different approach may be more suitable.
Final thoughts
Wegovy is not an overnight solution, and understanding the timeline from the start makes the treatment process significantly easier to navigate. Appetite changes come first, often within days. Visible weight loss follows over weeks. Progress in the early weeks is typically slow, but the evidence consistently shows that results build significantly over time.
The most important things you can do to support the process are to inject consistently, make meaningful changes to your diet, and stay in regular contact with your prescriber throughout. If progress feels slower than expected, a clinical conversation is always the right next step.
FAQ
How long does Wegovy take to work?
Wegovy begins acting from the first dose. Appetite changes are often noticed within 24 to 48 hours. Meaningful weight loss typically starts between weeks two and four, with the most significant results building between months three and twelve.
How long does it take for Wegovy to suppress appetite?
Most people notice some reduction in appetite within the first day or two of treatment. Consistent appetite suppression across the full week is usually established by weeks two to four, once blood levels of semaglutide have reached a steady state.
How long do you take Wegovy for weight loss?
Wegovy is designed as a long-term treatment. Clinical trial data measures outcomes at 68-72 weeks, and real-world evidence supports continued benefits with sustained use. Stopping early significantly increases the risk of weight regain.
When does weight loss start on Wegovy?
Most people begin to lose weight between weeks two and four. The first changes may be modest, partly reflecting water loss. More significant and consistent fat loss typically begins as the dose increases through the titration schedule.
Does Wegovy work faster at higher doses?
Yes. Results strengthen significantly at higher doses. Patients who reach the 2.4 mg maintenance dose consistently achieve better outcomes than those who remain on lower doses. The 7.2 mg dose, approved in January 2026, produces average weight loss of 20.7% over 72 weeks.
What if Wegovy is not working after two months?
Two months is still early in the titration schedule and too soon to judge effectiveness for most patients. Review your diet, check your dosing consistency, and speak to your prescriber if you have been at a therapeutic dose (1 mg or above) with no progress.
How long does it take to see results on Wegovy at 2.4 mg?
Most people on the 2.4 mg maintenance dose continue to lose weight for the full duration of treatment. Average weight loss of approximately 14.9% is achieved by 68 weeks in clinical trials, with results continuing to build throughout.
What does Wegovy do in the first week?
In the first week, most people notice subtle changes in appetite and fullness. The 0.25 mg starting dose is not expected to produce significant weight loss; its purpose is to allow the body to adjust to semaglutide and minimise side effects.
Where can I find official guidance on Wegovy?
The Wegovy patient information leaflet is available at medicines.org.uk. NICE guidance on semaglutide for weight management is at nice.org.uk/guidance/ta875. The MHRA Yellow Card scheme for reporting side effects is at yellowcard.mhra.gov.uk.
The DoktorABC medical advisory board
Dr. Roland Ruiken
Medical advisor, Norway
Dr. Viktor Simunovic
Medical advisor, Croatia